Progress of clinical therapies for dry age-related macular degeneration
Author:
Corresponding Author:

M. Valeria Canto-Soler. Department of Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO 80045, USA. valeria.canto-soler@cuanschutz.edu

Affiliation:

Clc Number:

Fund Project:

Supported by the Gates Family Fund, the Doni Solich Family Chair in Ocular Stem Cell Research, the CellSight Fund, and an Unrestricted Research Award from Research to Prevent Blindness?to the Department of Ophthalmology at the University of Colorado.

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Dry age-related macular degeneration (AMD) is a progressive blinding disease that currently affects millions of people worldwide with no successful treatment available. Significant research efforts are currently underway to develop therapies aimed at slowing the progression of this disease or, more notably, reversing it. Here the therapies which have reached clinical trial for treatment of dry AMD were reviewed. A thorough search of PubMed, Embase, and Clinicaltrials.gov has led to a comprehensive collection of the most recent strategies being evaluated. This review also endeavors to assess the status and future directions of therapeutics for this debilitating condition.

    Reference
    Related
    Cited by
Get Citation

Rhianna Rubner, Kang V. Li, M. Valeria Canto-Soler. Progress of clinical therapies for dry age-related macular degeneration. Int J Ophthalmol, 2022,15(1):157-166

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:February 17,2021
  • Revised:October 08,2021
  • Adopted:
  • Online: December 24,2021
  • Published: